Literature DB >> 22504072

Portal vein occlusion before major hepatectomy in patients with colorectal liver metastases: rationale, indications, technical aspects, complications and outcome.

C Lim1, O Farges.   

Abstract

Surgery is the only curative treatment for colorectal liver metastases (CRLM), but resection should be total with tumor-free margins and the remaining parenchyma, functionally evaluated. The rationale behind portal vein embolization (PVE) to reduce the risk of these hepatic resections is threefold: (i) surgery for CRLM has become more and more aggressive, and hepatocellular insufficiency represents the leading cause of mortality after major hepatectomy for hepatic metastasis (HM), (ii) underlying hepatic disease occurs more frequently than previously thought in these patients having undergone neoadjuvant chemotherapy, and can alter hepatic function and/or hinder postoperative regeneration, and (iii) the operative risk is increased if major hepatectomy is associated with resection of the primary tumor. The goal of this update is to review the reasons behind and the indications for PVE, to analyze the literature pertaining to whether PVE should be routine or selective, and to tackle certain technical aspects, all within the framework of the treatment of CRLM.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22504072     DOI: 10.1016/j.jviscsurg.2012.03.003

Source DB:  PubMed          Journal:  J Visc Surg        ISSN: 1878-7886            Impact factor:   2.043


  10 in total

1.  Tumour growth after portal vein embolization with pre-procedural chemotherapy for colorectal liver metastases.

Authors:  Lidewij Spelt; Ernesto Sparrelid; Bengt Isaksson; Roland G Andersson; Christian Sturesson
Journal:  HPB (Oxford)       Date:  2015-02-28       Impact factor: 3.647

Review 2.  [Assessment of resectability of colorectal liver metastases and extended resection].

Authors:  U Settmacher; H Scheuerlein; F Rauchfuss
Journal:  Chirurg       Date:  2014-01       Impact factor: 0.955

Review 3.  [Liver transection: modern procedure: Technique, results and costs].

Authors:  H Bruns; M W Büchler; P Schemmer
Journal:  Chirurg       Date:  2015-06       Impact factor: 0.955

Review 4.  Surgical resection techniques for locally advanced hilar cholangiocarcinoma.

Authors:  Sanjay Govil; Mettu Srinivas Reddy; Mohamed Rela
Journal:  Langenbecks Arch Surg       Date:  2014-06-04       Impact factor: 3.445

Review 5.  New paradigms in post-hepatectomy liver failure.

Authors:  Nicolas Golse; Petru O Bucur; René Adam; Denis Castaing; Antonio Sa Cunha; Eric Vibert
Journal:  J Gastrointest Surg       Date:  2012-11-18       Impact factor: 3.452

Review 6.  VEGF levels and the angiogenic potential of the microenvironment can affect surgical strategy for colorectal liver metastasis.

Authors:  Clarisse Eveno; Marc Pocard
Journal:  Cell Adh Migr       Date:  2012-11-01       Impact factor: 3.405

Review 7.  Tumour progression and liver regeneration--insights from animal models.

Authors:  Chetana Lim; Francois Cauchy; Daniel Azoulay; Olivier Farges; Maxime Ronot; Marc Pocard
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-04-09       Impact factor: 46.802

8.  ALPPS (associating liver partition and portal vein ligation for staged hepatectomy) does not affect proliferation, apoptosis, or angiogenesis as compared to standard liver resection for colorectal liver metastases.

Authors:  Katharina Joechle; Christian Moser; Petra Ruemmele; Katharina M Schmidt; Jens M Werner; Edward K Geissler; Hans J Schlitt; Sven A Lang
Journal:  World J Surg Oncol       Date:  2017-03-07       Impact factor: 2.754

9.  The transjugular approach is a safe and effective alternative for performing portal vein embolization.

Authors:  Ming-Shan Jiang; Xue-Feng Luo; Zhu Wang; Xiao Li
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

10.  Long-term survival of a patient with liver metastases from clear cell gastric adenocarcinoma after multimodality treatment including interventional oncology techniques: case report.

Authors:  Vesna Jugovec; Jernej Benedik; Jera Jeruc; Peter Popovic
Journal:  BMC Gastroenterol       Date:  2022-03-07       Impact factor: 3.067

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.